Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abiraterone acetate
- Development stage
- Approved
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Abiraterone acetate is an orally active, small molecule inhibitor of the enzyme cytochrome P450 17A1 (CYP17A1), which possesses both 17α-hydroxylase and 17,20-lyase activities. This enzyme is a critical catalyst in the biosynthesis of androgens, and its inhibition leads to the suppression of testosterone production in the testes, adrenal glands, and prostate tumor tissue. Developed by Cougar Biotechnology (a subsidiary of Johnson & Johnson), abiraterone acetate is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mHSPC). In the context of the COU-AA-206 Phase 1b clinical trial (NCT01400555), 'Cohort 2' specifically refers to the abiraterone acetate component being evaluated in combination with docetaxel and prednisone to determine the safety and recommended dose for chemotherapy-naïve patients.
- Brand names
- Zytiga
- Other names
- abirateroneCohort 2Cohort2Cohort-2
02
Targets
CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)CYP21A2 (Cytochrome P450 21-hydroxylase)
Beyond the preview
Go deeper on abiraterone acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abiraterone acetate.